SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert S. Johnson who wrote (82)10/9/1996 2:25:00 PM
From: rkrw   of 1154
 
The companies do not have many similarities, asides from their work on the human genome.

Incyte sells data on the human genome. They are not in the business of developing their own drugs. They help others do so for subscription fees to their database and other products.

Incyte has a pretty good thing going, they have around 9 big customers now, with a couple more, they should be profitable, which they expect to happen this quarter.

I believe Genome partners with firms to develop therapies together for development fees, royalties etc. More of a traditional biotech approach. Its more of a lt strategy than Incyte.

I am in no way saying one strategy is better than the other, merely pointing out the difference. I own neither but have looked into both.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News